Skip to content
  • March 4, 2009
  • General

ACADIA Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference on March 11, 2009

SAN DIEGO—(BUSINESS WIRE)—Mar. 4, 2009—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical companyutilizing innovative technology to fuel drug discovery and clinicaldevelopment of novel treatments for central nervous system disorders,today announced that it will present at the Barclays Capital GlobalHealthcare Conference on Wednesday, March 11, 2009, at 9:30 a.m. EasternTime at the Loews Miami Beach Hotel in Miami Beach, Florida.

A live webcast of ACADIA’s presentation will be accessible on thecompany’s website, www.acadia-pharm.com,under the investors section and an archived recording will be availableon the website through March 25, 2009.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments forcentral nervous system disorders. ACADIA is focused on developing aportfolio of its four most advanced product candidates, includingpimavanserin in Phase III for Parkinson’s disease psychosis, a productcandidate in Phase II for chronic pain and a product candidate in PhaseI for glaucoma, both in collaboration with Allergan, and ACP-106 inIND-track development. All of the product candidates in ACADIA’spipeline emanate from discoveries made using its proprietary drugdiscovery platform. ACADIA maintains a website at www.acadia-pharm.comto which ACADIA regularly posts copies of its press releases as well asadditional information and through which interested parties cansubscribe to receive email alerts.

Source: ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, InvestorRelations
Thomas H. Aasen, Vice President and ChiefFinancial Officer
858-558-2871

Important Note

You are now being redirected

You are now leaving acadia.com

You are about to leave acadia.com. You will be redirected to a third party website not affiliated with Acadia Pharmaceuticals Inc.
Do you want to continue?

You are leaving our {{LEAVING_REGION}} website and going to our {{ENTERING_REGION}} website, which is in {{ENTERING_LANGUAGE}}.
The information you are about to be referred to may not comply with the local regulatory requirements.
Do you want to continue?

You are now being directed to another Acadia website that contains information about specific treatment(s).
Do you want to continue?

Continue